News Breaks |
|
|
| March 4, 2013 |
| 19:11 EDT |  | APP, ASNA, SNTS, ACRX, CPWR, IPXL, TRLA, JCP | On The Fly: After Hours Movers
UP AFTER EARNINGS: American Apparel (APP), up 14.7%... Ascena Retail (ASNA), up 13.9%... Santarus (SNTS), up 9.5%... ALSO HIGHER: AcelRx (ACRX), up 10.2% after reporting a primary endpoint was reached in the a phase 3 trial for Sufentanil NanoTab PCA... Compuware (CPWR), up 5.1% after a Bloomberg report said the company has attracted buyout offers from private equity firms... LOWER: Impax (IPXL), down 17.5% after the company said the FDA completed its inspection of its Hayward manufacturing facility and issued a new form 483... Trulia (TRLA), down 5% after the company filed to sell $100M of common stock... J.C. Penney (JCP), down 2.7% after a 10M share block trade in the name priced between $16.40-$16.60. |
|
|
News For APP;ASNA;SNTS;ACRX;CPWR;IPXL;TRLA;JCP From The Last 14 Days Check below for free stories on APP;ASNA;SNTS;ACRX;CPWR;IPXL;TRLA;JCP the last two weeks. |
|
|
| May 23, 2013 |
| 14:58 EDT |  | JCP | J.C. Penney May volatility at eight-month lows
J.C. Penney overall option implied volatility of 52 is below its 26-week average of 62 according to Track Data, suggesting decreasing price movement. |
|
| May 22, 2013 |
| 16:12 EDT | | JCP | J.C. Penney enters into new $2.25B credit facility
J. C. Penney Company announced that its wholly owned subsidiary, J. C. Penney Corporation, has entered into a new five-year $2.25B senior secured term loan credit facility. The size of the facility was increased from the $1.75B anticipated in the commitment letter the company announced on April 29. |
|
| 07:28 EDT |  | IPXL | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 21, 2013 |
| 16:21 EDT |  | CPWR | Compuware sees FY14 GAAP EPS 35c-37c, consensus 42c
 Subscribe for More Information |
|
| 16:18 EDT | | CPWR | Compuware reports Q4 non-GAAP EPS 5c, consensus 5c
Subscribe for More Information |
|
| 15:18 EDT | | CPWR | Notable companies reporting after market close
Subscribe for More Information |
|
| 09:29 EDT |  | ACRX | AcelRx rises after positive Phase 3 of of Sufentanil PCA system
Subscribe for More Information |
|
| 08:56 EDT | | JCP | J.C. Penney announces successful tender, consent solicitation for debentures
Subscribe for More Information |
|
| 08:05 EDT | | ACRX | AcelRx to host a webcast
Subscribe for More Information |
|
| 07:36 EDT | | ACRX | AcelRx announces positive results from Phase 3 study of Sufentanil PCA system
Subscribe for More Information |
| |
| May 20, 2013 |
| 10:23 EDT | | JCP | J.C. Penney advances after analyst hikes price target to $27
Subscribe for More Information |
|
| 10:11 EDT |  | JCP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:16 EDT | | JCP | Follow-up: J.C. Penney upgraded to Buy from Hold at Maxim
Maxim upgraded J.C. Penney on expectations the company's strategy changes under new CEO Mike Ullman will drive traffic. The firm said its recent channel checks indicate that store traffic has increased and it raised its price target for shares to $27 from $16.50. |
|
| 08:03 EDT | | JCP | J.C. Penney upgraded to Buy from Hold at Maxim
|
|
| 07:30 EDT |  | JCP | J.C. Penney price target lowered to $7 from $12 at BMO Capital
Subscribe for More Information |
|
| May 17, 2013 |
| 10:55 EDT | | JCP | J.C. Penney drops after results miss expectations
Subscribe for More Information |
|
| 10:36 EDT | | SNTS | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 10:18 EDT | | CPWR | Compuware June volatility increases into Q4 and outlook
Subscribe for More Information |
|
| 09:48 EDT | | JCP | J.C. Penney falls after earnings miss, levels to watch
Subscribe for More Information |
|
| 08:41 EDT | | IPXL | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
| |
|
|
|
|
